Q2 2026 Illumina Inc Earnings Call Transcript
Key Points
- Revenue grew at the fastest rate since CEO Jacob Thaysen joined, with Rest of World organic growth of 8.1% in Q2, exceeding guidance.
- Clinical markets remain a primary growth driver, with Rest of World clinical consumables growing 15% ex China and US/Canada growing above 20%.
- NovaSeq X demand remains strong with over 95 placements in Q2, and the installed base expansion is expected to support consumables growth for years.
- The company raised its full-year 2026 guidance for Rest of World organic revenue growth to greater than 5% and EPS to $5.30-$5.40.
- New multiomics offerings, including StrataMap Spatial and SomaScan/SomaSeq, are gaining traction, and the Billion Cell Atlas has secured six biopharma partners, contributing to revenue.
- Non-GAAP gross margin of 68.2% and operating margin of 22.5% came in above guidance despite higher freight and memory costs.
- The company repurchased shares and maintains a strong balance sheet with $1.17 billion in cash and a leverage ratio of 1.6 times.
- Management expressed confidence in achieving high single-digit revenue growth in 2027, supported by the expanding NovaSeq X installed base and clinical momentum.
- Research and applied markets consumables declined 7% Rest of World, with customers cautious due to funding uncertainty, and the company expects mid- to high single-digit declines for the year.
- Sequencing consumables growth in clinical markets slowed sequentially from 20% to 15%, partly due to dynamics in the Middle East and Latin America.
- The company faces headwinds from rising memory and freight costs, which were higher than anticipated and absorbed in Q2 results.
- Q3 guidance implies a step-down in Rest of World organic revenue growth to approximately 4.5%, reflecting tougher instrument comparisons and seasonality.
- The transition to NovaSeq X is still ongoing, with only 59% of revenue on the platform, and the company expects clinical volume conversion to reach 80-85% by end of 2026, indicating continued transition dynamics.
- Instrument placements are expected to moderate in the second half of 2026, with growth rates slowing against tougher comparisons.
- The company noted that the mid-throughput instrument segment is more sensitive to the macro environment and has been muted.
- Cash flow from operations was below trend due to timing of tax payments and higher inventory levels as the company secured supply for critical components.
Good day, ladies and gentlemen. Welcome to the second quarter 2026 Illumina earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the call over to Head of Investor Relations, Conor McNamara.
Hello, everyone, and welcome to Illumina's second quarter 2026 earnings call. Today, we will review our financial results released after market close and provide prepared remarks before opening the line for questions and answers. Our earnings release is available in the Investor Relations section of illumina.com.
Joining me today are Jacob Thaysen, Chief Executive Officer; and Ankur Dhingra, Chief Financial Officer. Jacob will begin with an update on Illumina's business, followed by Ankur's review of the financials.
We will be discussing certain non-GAAP financial measures, and a reconciliation to GAAP can be found in today's release and in the supplementary data on our website. Unless otherwise stated, all
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
